Promoted Content
Promoted Content

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): TCRT-ESO-A2

            Therapeutic Area: Oncology Product Name: TCRT-ESO-A2

            Highest Development Status: IND Enabling Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: PharmaEssentia

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration October 13, 2020

            Details:

            Axis Therapeutics and PharmaEssentia will collaborate to conduct an initial clinical study of Axis Therapeutics’ TCRT-ESO-A2 therapy, targeting solid tumors that are NY-ESO-1 positive in HLA-A positive patients, and to manufacture the investigational products, in Taiwan.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): SACT-1

            Therapeutic Area: Oncology Product Name: SACT-1

            Highest Development Status: IND Enabling Product Type: Undisclosed

            Partner/Sponsor/Collaborator: H.C. Wainwright & Co.

            Deal Size: $9.0 million Upfront Cash: Undisclosed

            Deal Type: Public Offering October 02, 2020

            Details:

            Aptorum Group intends to use the net proceeds to conduct further analyses of SACT-1 and ALS-4, currently on track for IND submission to commence Phase 1b/2a clinical trials and undergoing final stages of IND enabling studies for Phase 1 human clinical trials respectively.